SMS Lifesciences India Ltd. (IN:HALEOSLABS)
:HALEOSLABS
Want to see IN:HALEOSLABS full AI Analyst Report?
HALEOSLABS Stock Chart & Stats
₹1105.00
₹4.55(0.36%)
At close: 4:00 PM EST
₹1105.00
₹4.55(0.36%)
Day’s Range― - ―
52-Week Range₹1,050.05 - ₹1,571.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)154.00
Market Cap
₹4.46B
Enterprise Value₹5.23B
Total Cash (Recent Filing)₹11.92M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)14.0
Beta0.78
Next Earnings
Jun 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)21.89
Shares Outstanding3,023,287
10 Day Avg. Volume53
30 Day Avg. Volume154
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)2.00
Price to Sales (P/S)1.17
P/FCF Ratio21.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Revenue GrowthSustained ~62.6% revenue growth shows durable demand for SMS Lifesciences' APIs across domestic and export channels. Higher top-line traction strengthens scale economics, supports reinvestment in capacity, and increases resilience to single-product shocks over the medium term.
Strong Margin ProfileReported strong EBIT/EBITDA margins and improving net profit margin signal structural profitability and operational efficiency in small-molecule API production. Consistent margins support internal cash generation and the ability to absorb input cost swings while funding growth without persistent external financing.
Balanced Leverage & Solid ROEA reasonable debt-to-equity level alongside solid return on equity indicates efficient capital use and manageable leverage. This balance supports funding incremental capacity or customer qualification investments while keeping default and refinancing risk contained in normal cycles.
Bears Say
Cash Flow VolatilityDespite recent free cash flow improvement, documented historical inconsistencies imply operational cash conversion can fluctuate. Variable cash flows can constrain scheduled capex, delay customer qualification projects, and limit steady deleveraging or dividend policies over the medium term.
Gross Margin VolatilityReported volatility in gross profit margin points to exposure to raw-material pricing, yield variability or production inefficiencies. For an API manufacturer, persistent gross-margin swings can erode sustainable profitability and require ongoing investments in process control and procurement discipline.
Moderate Reliance On LiabilitiesA moderate reliance on liabilities reduces balance-sheet flexibility in economic stress and can raise funding costs if market conditions tighten. For capital-intensive API manufacturing, this reliance may limit competitive agility for new molecule qualification or capacity expansion during downturns.
SMS Lifesciences India Ltd. News
HALEOSLABS FAQ
What was SMS Lifesciences India Ltd.’s price range in the past 12 months?
SMS Lifesciences India Ltd. lowest stock price was ₹1050.05 and its highest was ₹1571.10 in the past 12 months.
What is SMS Lifesciences India Ltd.’s market cap?
SMS Lifesciences India Ltd.’s market cap is ₹4.46B.
When is SMS Lifesciences India Ltd.’s upcoming earnings report date?
SMS Lifesciences India Ltd.’s upcoming earnings report date is Jun 01, 2026 which is in 31 days.
How were SMS Lifesciences India Ltd.’s earnings last quarter?
Currently, no data Available
Is SMS Lifesciences India Ltd. overvalued?
According to Wall Street analysts SMS Lifesciences India Ltd.’s price is currently Overvalued.
Does SMS Lifesciences India Ltd. pay dividends?
SMS Lifesciences India Ltd. pays a Annually dividend of ₹1.5 which represents an annual dividend yield of 0.12%. See more information on SMS Lifesciences India Ltd. dividends here
What is SMS Lifesciences India Ltd.’s EPS estimate?
SMS Lifesciences India Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Lifesciences India Ltd. have?
SMS Lifesciences India Ltd. has 3,023,287 shares outstanding.
What happened to SMS Lifesciences India Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SMS Lifesciences India Ltd.?
Currently, no hedge funds are holding shares in IN:HALEOSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Lifesciences India Ltd.
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
Technical Analysis
Brooks Laboratories Limited
―
Lyka Labs Limited
―
Medico Remedies Ltd.
―
Nureca Ltd.
―
SMS Pharmaceuticals Limited
―